It has been reported that the anti–diabetic PPAR agonists are also effective in cardiovascular disease (CVD) [17,18,19], thyroid [20,21], colorectal [21], and lung cancer [22] and chronic myeloid leukemia (CML) [23,24,25]. The gene discussed is PPARA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.